COVID-19 pandemic challenges for dermatology

Evgenia V. Dvoryankova

For citation:

Abstract

COVID-19 pandemic posed a number of new formidable challenges to medical community. Dermatologists have not only to detect, define and reverse the new coronavirus infection cutaneus manifestations, but also to provide medical assistance to colleagues with occupational dermatitis due to personal protective equipment use. Moreover, it is necessary to provide quality medical care to patients with acute and chronic dermatosis given the limitations of present pandemic situation.

Key words: dermatology, COVID-19, pandemic.

References

1. Lu R, Zhao X, Li J et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395 (10224): 565–74.

2. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020. DOI: 10.1111/jdv. 16387

3. Zhang Y, Cao W, Xiao M et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acroischemia. Zhonghua Xue Ye Xue Za Zhi 2020; 41: E006.

4. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020. DOI: 10.1111/all.14238

5. Zheng Y, Lai W. Dermatology staff participate in fight against Covid-19 in China. J Eur Acad Dermatol Venereol 2020. DOI: 10. 1111/jdv.16390

6. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104 (3): 246–51.

7. Jin Y-H, Lin C, Cheng Z-S et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7: 4.

8. Yan Y, Chen H, Chen L et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for healthcare workers fighting against coronavirus disease 2019. Dermatol Ther 2020; e13310. DOI: 10.1111/dth.13310

9. Lan J, Song Z, Miao X et al. Skin damage among healthcare workers managing coronavirus disease-2019. J Am Acad Dermatol 2020; PII: S0190-9622 (20): 30392–3. DOI: 10.1016/j.jaad.2020. 03.014

10. Lin P, Zhu S, Huang Y et al. Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. Br J Dermatol 2020. DOI: 10.1111/bjd.19089

11. Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australia/New Zealand consensus statement. Australas J Dermatol 2020. DOI: 10.1111/ajd.13313

12. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395 (10223): 473–5.

13. Baysham AM, Feldman SR. Should patients stop their biologic treat- ment during the COVID-19 pandemic. J Dermatol Treat 2020; 1–2. DOI: 10.1080/09546634.2020.1742438

14. Camus P. The drug-induced respiratory disease website, Pneumotox Online V2.2. http://www.pneumotox.com. Assessed April 7, 2020.

For citation:Dvoryankova E.V. COVID-19 pandemic challenges for dermatology. Clinical review for general practice. 2020; 1: 14–17.

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice